CDMO– tag –
-
Made Scientific and Pluristyx Announce Integrated iPSC Development & Manufacturing Partnership to Accelerate Next-Generation iPSC-Derived Cell Therapies
PR Newswire USA Overview Made Scientific, a cell therapy CDMO, and Pluristyx, an iPSC platform technology provider, announced an integrated iPSC development and manufacturing partnership. This collaboration aims to accelerate the clinica... -
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
Single-Use Cell Culture Bag Market Anticipated for Strong Growth by 2033, Driven by Efficiency and Contamination Reduction
Pando Japan Overview The single-use cell culture bag market is projected for substantial growth from 2026 to 2033, primarily fueled by technological advancements that enhance process efficiency and significantly mitigate contamination ri... -
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in... -
Europe’s Biotech Vanguard: Ori Biotech’s Modular Automation Reshapes Cell and Gene Therapy Manufacturing
PharmTech ヨーロッパ Overview European biotechnology firms are pioneering advanced manufacturing solutions to overcome critical production hurdles in cell and gene therapies. Ori Biotech, in strategic collaborations with Cell Therapies, ... -
FUJIFILM Cellular Dynamics Quadruples iPSC Manufacturing Capacity with $200M New Facility in Wisconsin, Meeting Soaring Cell Therapy Demand
Manufacturing Dive USA Overview FUJIFILM Cellular Dynamics (FCDI) has inaugurated a new headquarters and iPSC development and manufacturing facility in Madison, Wisconsin, backed by a $200 million investment. This 170,000 square-foot exp... -
FUJIFILM Diosynth Biotechnologies Secures 10-Year Biologics Manufacturing Deal with Regeneron
PharmaSource USA Overview FUJIFILM Diosynth Biotechnologies has inked a significant 10-year manufacturing agreement with Regeneron for the large-scale production of its biologics. This long-term partnership fortifies Fujifilm's position ... -
Lonza Completes Pure-Play CDMO Transition, Reports Strong Q1 2026 Driven by Robust Demand
TipRanks.com USA Overview Lonza announced strong Q1 2026 results, propelled by robust demand for its CDMO services, and completed the divestment of its Capsules & Health Ingredients division. This strategic move cements Lonza's posit...
